Serum oncoproteins and growth factors in asbestosis and silicosis patients.
Brandt-Rauf-PW; Smith-S; Hemminki-K; Koskinen-H; Vainio-H; Niman-H; Ford-J
Int J Cancer 1992 Apr; 50(6):881-885
Serum levels of oncoproteins and growth factors in asbestosis and silicosis patients were examined. The study cohort consisted of 46 patients (36 asbestosis and ten silicosis) who supplied serum samples between March 1983 and August 1987. Followup study through June 1991 showed that 15 from the asbestosis group and three from the silicosis group developed cancer. Blood samples were analyzed for increased levels of the oncoproteins ras, myc, myb, fes, src, int-1, and mos, as well as for transforming growth factor-beta-1 and platelet-derived-growth-factor-B (PDGF); analysis involved monoclonal antibodies against marker peptide sequences and serial dilution with densitometry. Fifty of the 91 samples were positive for at least one of the oncoproteins or growth factors. Elevated oncoproteins were found only in the asbestosis patients, while elevated PDGF occurred in both asbestosis and silicosis patients. Only the ras oncogene (p21) protein was significantly elevated. The relationship between elevated PDGF levels and advanced pneumoconiosis was also significant. There was a greater tendency for patients with progressive pneumoconiosis to be PDGF positive. The authors conclude that elevated serum p21 may be a useful marker for early diagnosis of pulmonary cancer and that elevated PDGF may serve as a marker of progressive and advanced pneumoconiosis.
NIOSH-Publication; NIOSH-Grant; Cancer; Growth-factors; Blood-analysis; Immunological-tests; Epidemiology; Carcinogenesis; Lung-cancer; Respiratory-system-disorders
Environmental Sciences Columbia University Sch of PH 60 Haven Avenue/b-1 Level New York, NY 10032
International Journal of Cancer
Columbia University New York, New York, New York